Literature DB >> 23860343

N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases.

Mary J Holmay1, Melissa Terpstra, Lisa D Coles, Usha Mishra, Matthew Ahlskog, Gülin Öz, James C Cloyd, Paul J Tuite.   

Abstract

OBJECTIVE: This study aimed to determine if the antioxidant N-acetylcysteine (NAC) is able to alter peripheral and central redox capabilities in patients with Parkinson disease (PD) or Gaucher disease (GD).
METHODS: The study included nondemented adult subjects: 3 with PD, 3 with GD, and 3 healthy controls. Baseline brain glutathione (GSH) concentrations were measured using 7-T magnetic resonance spectroscopy (MRS). Baseline blood reduced-to-oxidized GSH ratios were determined for each subject. Brain GSH concentrations and blood redox ratios were then determined during and at specified time points after a single, 150-mg/kg NAC infusion.
RESULTS: N-acetylcysteine increased blood GSH redox ratios in those with PD and GD and healthy controls, which was followed by an increase in brain GSH concentrations in all subjects.
CONCLUSIONS: This is the first demonstration that with MRS, it is possible to directly measure and monitor increases in brain GSH levels in the human brain in response to a single, intravenous administration of NAC. This work shows the potential utility of MRS monitoring, which could assist in determining dosing regimens for clinical trials of this potentially useful antioxidant therapy for PD disease, GD, and other neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860343      PMCID: PMC3934795          DOI: 10.1097/WNF.0b013e31829ae713

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  28 in total

1.  Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine.

Authors:  R W Hurd; B J Wilder; W R Helveston; B M Uthman
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 2.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

3.  Blood oxidative stress markers in Gaucher disease patients.

Authors:  Fernanda M Roversi; Luciano C Galdieri; Bruno H C Grego; Fernanda G Souza; Cecília Micheletti; Ana Maria Martins; Vânia D'Almeida
Journal:  Clin Chim Acta       Date:  2005-08-24       Impact factor: 3.786

4.  Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations.

Authors:  Gülin Oz; Melissa Terpstra; Ivan Tkác; Pratibha Aia; Jodi Lowary; Paul J Tuite; Rolf Gruetter
Journal:  Magn Reson Med       Date:  2006-02       Impact factor: 4.668

5.  Proteasomal dysfunction in sporadic Parkinson's disease.

Authors:  Kevin St P McNaught; Tehone Jackson; Ruth JnoBaptiste; Alexander Kapustin; C Warren Olanow
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse.

Authors:  Koji Aoyama; Sang Won Suh; Aaron M Hamby; Jialing Liu; Wai Yee Chan; Yongmei Chen; Raymond A Swanson
Journal:  Nat Neurosci       Date:  2005-11-27       Impact factor: 24.884

Review 7.  Oxidatively modified proteins in aging and disease.

Authors:  M Flint Beal
Journal:  Free Radic Biol Med       Date:  2002-05-01       Impact factor: 7.376

8.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.

Authors:  J Sian; D T Dexter; A J Lees; S Daniel; Y Agid; F Javoy-Agid; P Jenner; C D Marsden
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

9.  Analysis of macromolecule resonances in 1H NMR spectra of human brain.

Authors:  K L Behar; D L Rothman; D D Spencer; O A Petroff
Journal:  Magn Reson Med       Date:  1994-09       Impact factor: 4.668

10.  Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress.

Authors:  Marta Deganuto; Maria Gabriela Pittis; Alex Pines; Silvia Dominissini; Mark R Kelley; Rodolfo Garcia; Franco Quadrifoglio; Bruno Bembi; Gianluca Tell
Journal:  J Cell Physiol       Date:  2007-07       Impact factor: 6.384

View more
  64 in total

1.  Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo.

Authors:  Negin Nouraei; Lauren Zarger; Justin N Weilnau; Jimin Han; Daniel M Mason; Rehana K Leak
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-12       Impact factor: 4.219

2.  Sensitivity and specificity of human brain glutathione concentrations measured using short-TE (1)H MRS at 7 T.

Authors:  Dinesh K Deelchand; Małgorzata Marjańska; James S Hodges; Melissa Terpstra
Journal:  NMR Biomed       Date:  2016-02-22       Impact factor: 4.044

3.  Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency.

Authors:  Sarah Doss; Jan Leo Rinnenthal; Tanja Schmitz-Hübsch; Alexander U Brandt; Sebastian Papazoglou; Silke Lux; Stephan Maul; Jens Würfel; Matthias Endres; Thomas Klockgether; Martina Minnerop; Friedemann Paul
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

4.  Redox Potential-Sensitive N-Acetyl Cysteine-Prodrug Nanoparticles Inhibit the Activation of Microglia and Improve Neuronal Survival.

Authors:  Eleni Markoutsa; Peisheng Xu
Journal:  Mol Pharm       Date:  2017-04-04       Impact factor: 4.939

5.  Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

Authors:  Ragy R Girgis; Seth Baker; Xiangling Mao; Roberto Gil; Daniel C Javitt; Joshua T Kantrowitz; Meng Gu; Daniel M Spielman; Najate Ojeil; Xiaoyan Xu; Anissa Abi-Dargham; Dikoma C Shungu; Lawrence S Kegeles
Journal:  Psychiatry Res       Date:  2019-03-12       Impact factor: 3.222

6.  Advanced single voxel 1 H magnetic resonance spectroscopy techniques in humans: Experts' consensus recommendations.

Authors:  Gülin Öz; Dinesh K Deelchand; Jannie P Wijnen; Vladimír Mlynárik; Lijing Xin; Ralf Mekle; Ralph Noeske; Tom W J Scheenen; Ivan Tkáč
Journal:  NMR Biomed       Date:  2020-01-10       Impact factor: 4.044

Review 7.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 9.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

10.  Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid.

Authors:  Reno C Reyes; Giordano Fabricio Cittolin-Santos; Ji-Eun Kim; Seok Joon Won; Angela M Brennan-Minnella; Maya Katz; Graham A Glass; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.